Professor Szabo is an internationally recognized expert in the fields of oxidative and nitrosative stress, gaseous transmitters, cell death, cell dysfunction, cardiovascular, and inflammatory mechanisms. In the mid 90's he has pioneered the concept that identified the pathogenetic role of the nuclear enzyme PARP in promoting cell necrosis, and its roles in cardiovascular and inflammatory diseases. His applied research and development work in this area led to novel drug candidates that have progressed into clinical trials. Over the last decade, he has developed a significant track record in the biology of hydrogen sulfide, where he has identified multiple regulatory roles of this mediator in angiogenesis, reperfusion injury and cancer. His background (two Ph.D. degrees in physiology and pharmacology, coupled with his medical background [M.D.]) and his diverse research interests, which range from basic cell death mechanisms to vascular injury, diabetes, shock, heart failure, inflammatory diseases, diabetes and its complications) as well as his dual activities in academia (basic research) and in industry (applied research and drug development) are substantial. His expertise range from the regulation of nitric oxide synthases, through oxidant and antioxidant mechanisms including peroxynitrite, and cellular inflammatory mechanisms and pathways including neuroimmunomodulation, and the bacterial protein flagellin. His background and expertise are internationally recognized in the pathogenesis of circulatory shock, diabetes, myocardial infarction, cardiomyopathy, stroke, neuroinflammation, and diabetic complications. He has published over 500 original research articles has been in the top 10 most cited pharmacologists in the world for the last decade. He was recently listed as one of the top 400 most infuential biomedical scientists in the word. He has been continuously funded by the National Institutes of Health since 1995, and has recieved a cumulative extramural funding of over $15 million. Currently at the Department of Anesthesiology at the University of Texas Medical Branch, Professor Szabo leads a multidisciplinary team of investigators with expertise in molecular biology, cell biology, pharmacology, physiology, pathophysiology, medicinal chemistry and translational science. Professor Szabo has received numerous awards, including the Novartis Award of the British Pharmacological Society and the Dennis Gabor Innovation Award, and the Texas Star Award. He serves or served on the Editorial Board of numerous leading journals, including the British Journal of Pharmacology, the Journal of Pharmacology and Experimental Therapeutics, Shock, and Molecular Medicine. He is an Elected Fellow of the British Pharmacological Society and an Elected Member of the American Society for Clinical Investigation.
Dr. Estenssoro is the Medical Director of the Critical Care Unit of the Hospital Interzonal de Agudos San Martin de La Plata, Buenos Aires, in Argentina. Her main focus of research involves clinical epidemiology of ARDS, sepsis and septic shock, chronic critical illness, obstetric critical care and, generally, outcomes research in the ICU.
Dr. Estenssoro was President of the Argentinian Society of Intensive Care Medicine (SATI). She has served in the Critical Care Assembly of the American Thoracic Society as Chair of the International Affairs Committee, and serves as member of the Program Committee since 2010. Dr. Estenssoro has taught in the Latin-American Section of the course Methods in Epidemiology and Operations Research (MECOR), from the American Thoracic Society.
Dr. Prescott is an intensivist and researcher at the University of Michigan and Ann Arbor Veterans Affairs Hospital in the United States. Her research examines how sepsis shapes a patient’s broader trajectory, and how we can reduce post-sepsis morbidity. She is a rising star in the field of sepsis survivorship.
Dr. Prescott’s research has taught us about the high rate of post-acute care use, hospital readmission, and late death in sepsis survivors. She has shown that many survivors die following hospital re-admissions for infections, suggesting that post-sepsis immune-suppression is an enduring problem that contributes to late sepsis-related deaths. She has also shown that microbiome disruption increases risk for subsequent sepsis. Taken together, her research has highlighted the role of specific treatable medical conditions in driving post-sepsis morbidity. Her research is funded by the US National Institutes of Health and the Department of Veteran’s Affairs.
Professor of Therapeutics and Critical Care Medicine, at the University Paris-South in France.
Clinical activity at the Medical ICU of the Bicêtre University Hospital next to Paris.
Research interests in heart-lung interactions, cardiovascular performance, regional blood flow assessment, tissue oxygenation, haemodynamic monitoring, and assessment of volume status in critically ill patients. Proposals of new tests to assess fluid responsiveness such as Pulse Pressure Variation and Passive Leg Raising.
189 articles (referenced in Pubmed) and around 122 book chapters/didactic articles, almost of them in the field of haemodynamics.
Editor-in-Chief of Annals of Intensive Care.
636 invited lectures including 465 in international congresses.
Currently Chair of the cardio-dynamics section of the European Society of Intensive Care Medicine (ESICM).
Dr. Kissoon is Past President of the World Federation of Pediatric Intensive and Critical Care Societies (WFPICCS); Vice-President, Medical Affairs at British Columbia (BC) Children’s Hospital and Professor, Pediatric and Surgery at the University of British Columbia (UBC) in Vancouver, Canada. He holds the UBC BC Children’s Hospital Endowed Chair in Acute and Critical Care for Global Child Health, is Vice Chair, Global Alliance for Sepsis (GSA), co-Chair, World Sepsis Day, International Pediatric Sepsis Initiative, and the Pediatric Surviving Sepsis Campaign Guideline Committee.
As the Vice Chair of the Global Sepsis Alliance, Dr. Kissoon has been instrumental in lobbying the World Health Assembly of the United Nations to adopt a resolution on sepsis which has recently been passed in May 2017 at the World Health Assembly
In recognition of his achievements, in 2013 Dr. Kissoon was awarded the Distinguished Career Award by the AAP for his contribution to the society and discipline, in 2015 he was awarded the SCCM Master of Critical Care Medicine award and the BNS Walia PGIMER Golden Jubilee Oration Award in India. In 2016 Dr. Kissoon received the UBC Canada Distinguished Achievement Award for Overall Excellence and in 2017, Dr. Kissoon has for the 6th time received a Presidential Citation from the Society of Critical Care Medicine for outstanding contributions to the Society (this was previously awarded to him in 2001, 2003, 2012, 2013 and 2014).
Simon Finfer is a Professorial Fellow in the Critical Care and Trauma Division at The George Institute for Global Health. He is a practicing critical care physician with an appointment as a Senior Staff Specialist at Royal North Shore Hospital and Director of Intensive Care at the Sydney Adventist Hospital, the largest not-for-profit hospital in New South Wales.
Simon is an Professor at the University of New South Wales, and a Clinical Professor at the University of Sydney. He is a past-Chair of the Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. He chairs the Council of the International Sepsis Forum, and is a member (Treasurer) of the Global Sepsis Alliance Executive. Simon is a member of the World Sepsis Day Steering Committee and recently co-chaired the 1st World Sepsis Congress, a two-day free online congress that attracted 14,000 registrants.
His postgraduate qualifications include Fellowships of the Royal Colleges of Physicians, the Royal College of Anaesthetists and the College of Intensive Care Medicine. He was elected to the ANZICS Honour Roll in 2011 and in 2012 he was awarded an honorary doctorate (Doctor of Medicine) by The Friedrich-Schiller University in Germany, an honour awarded once every 10 years. He is a Fellow of the Australian Academy of Health and Medical Sciences.
Simon’s major research interest is the design and conduct of large scale randomised controlled trials in critical care. Simon is active in forging major international research collaborations that have conducted large scale clinical trials and epidemiological research to improve the treatment of critically ill and injured patients. He has published over 150 peer reviewed papers, many in the most prestigious journal in the world. He is frequently invited to lecture at major international conferences.